Prescription medicine
Zavegepant Brand names: Zavzpret
Zavegepant (Zavzpret) is a prescription medicine with an FDA approval on record since 2023. No generic is listed; pharmacies paid $189.80 per unit (Zavzpret 10 mg nasal spray) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the zavegepant FDA label on DailyMed (effective August 11, 2025, Pfizer Laboratories Div Pfizer Inc); the NDA 216386 record on Drugs@FDA; every zavegepant label on DailyMed.
Highlights of the record
FDA label of August 11, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 10 mg/.1ml
Spray.
On the market
- Earliest approval on file
- March 9, 2023 Zavzpret, Pfizer; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- June 26, 2034 Zavzpret spray; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $189.80 per unit Zavzpret 10 mg nasal spray
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 857 through July 30, 2026
What is zavegepant used for?
From the label: indications and usageZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine.
Conditions named in the indications of zavegepant's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Calcitonin Gene-related Peptide Receptor Antagonist.
Source: FDA drug label (ZAVZPRET), Pfizer Laboratories Div Pfizer Inc, effective August 11, 2025 (SPL set 9c4a7aec-daef-4961-ba77-92f4b58be780), via openFDA; the full label on DailyMed
Is there a generic for zavegepant (Zavzpret)?
No generic zavegepant is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 1 patent for Zavzpret spray: the compound patent runs to June 26, 2034. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2023 earliest approval on file
- 2034 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for zavegepant (Zavzpret)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $189.80 per unit (Zavzpret 10 mg nasal spray), up 5% from $181.16 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Zavzpret 10 mg nasal spray (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Zavzpret 10 mg nasal spray | Brand | $189.80 per unit | n/a | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for zavegepant?
The FDA Adverse Event Reporting System holds 857 reports that list zavegepant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 0 are coded as a death and 21 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as zavegepant?
3 other medicines are given the same way (nasal) and in the same FDA class as zavegepant or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (nasal) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 5 labelers | $16.51 per unit 20 mg nasal spray | No current entry |
| Dihydroergotamine | Migraine | 5 labelers | $29.44 per mL 4 mg/mL nasal spray | No current entry |
| Zolmitriptan | Migraine | 2 labelers | $44.04 per unit 5 mg nasal spray | No current entry |
Every medicine labeled for the same conditions as zavegepant
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to zavegepant
- 3 medicines for the same use
- Other calcitonin gene-related peptide receptor antagonists
- the pharmacologic class, with prices and generics
- Zavegepant side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other